Why Abzena?
Our focused approach.
With the rising numbers of protein-based therapeutics entering the development pipeline and increased competition, there is growing pressure for drug developers to reduce timelines to regulatory submissions. Cell line development (CLD) plays a critical role in this process and can greatly aid in de-risking and reducing the time to file. However, drug developers must be aware that your technology, approach, and overall strategy can make or break your program’s chances of downstream success.
Having an integrated approach to CLD that aims for increased speed to IND while ensuring the product is of high quality is essential. A robust CLD strategy will incorporate methods and techniques that minimize delays and risks by gathering information on cell line and molecule developability and manufacturability as early as possible. Leveraging next-generation technology platforms, like AbZelectPRO™, aid in increasing CLD productivity and efficiency, which expedite the development pathway and reduces risks and costs. Register for this webinar today to gain insights on how enhanced CLD technologies can achieve higher-producing stable pools faster in early-stage development to increase your program’s chances of success.
Daniel Giroux, Vice President of Process Development and Analytical Method Development
Simon Keen, Vice President of Cell Line Development